Cardiomyopathy Trial, Recruiting (NCT07633587)

Cardiomyopathy Trial, Recruiting NCT07633587 Sponsor: Groupe Hospitalier Pitie-Salpetriere Condition: Cardiomyopathy

Printed from Voxsanity (voxsanity.com.au) — NCT07633587 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Cardiomyopathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are a cancer patient who has received at least one immunotherapy drug known as an immune checkpoint inhibitor
You have been recorded in an international registry as possibly, probably, or definitely having developed heart inflammation (myocarditis) linked to your immune checkpoint inhibitor treatment
Information about when your symptoms first appeared or when you were diagnosed is available
Information about what happened to you over time, including survival information, is available

Who may not be able to join:

Your records appear more than once in the registry (duplicate entries)
There is not enough medical information available to confirm a diagnosis of heart inflammation (myocarditis)
Your records have been withdrawn from research use, or there are unresolved data quality problems that prevent your information from being included in the study's analysis (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0033142178531

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07633587

Sponsor: Groupe Hospitalier Pitie-Salpetriere

Phase: Not Applicable

Status: Recruiting

Condition: Cardiomyopathy

Trial contact: 0033142178531

More information: https://clinicaltrials.gov/study/NCT07633587

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are a cancer patient who has received at least one immunotherapy drug known as an immune checkpoint inhibitor
You have been recorded in an international registry as possibly, probably, or definitely having developed heart inflammation (myocarditis) linked to your immune checkpoint inhibitor treatment
Information about when your symptoms first appeared or when you were diagnosed is available
Information about what happened to you over time, including survival information, is available

Who may not be able to join:

Your records appear more than once in the registry (duplicate entries)
There is not enough medical information available to confirm a diagnosis of heart inflammation (myocarditis)
Your records have been withdrawn from research use, or there are unresolved data quality problems that prevent your information from being included in the study's analysis (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Groupe Hospitalier Pitie-Salpetriere

Registry

ClinicalTrials.gov

Start date

20 May 2026

Est. completion

1 October 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

All-cause mortality at 90 days after ICI-M presentation/index date

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov